Cargando…

应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509625/
https://www.ncbi.nlm.nih.gov/pubmed/37749040
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.011
_version_ 1785107775964053504
collection PubMed
description
format Online
Article
Text
id pubmed-10509625
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-105096252023-09-21 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2023-07 /pmc/articles/PMC10509625/ /pubmed/37749040 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.011 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 短篇论著
应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title_full 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title_fullStr 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title_full_unstemmed 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title_short 应用BTK抑制剂治疗的B细胞淋巴瘤患者感染情况分析
title_sort 应用btk抑制剂治疗的b细胞淋巴瘤患者感染情况分析
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509625/
https://www.ncbi.nlm.nih.gov/pubmed/37749040
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.011
work_keys_str_mv AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī
AT yīngyòngbtkyìzhìjìzhìliáodebxìbāolínbāliúhuànzhěgǎnrǎnqíngkuàngfēnxī